Idioma:

Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial

Medeiros-Ribeiro, Ana C ; Aikawa, Nadia E ; Saad, Carla G S ; Yuki, Emily F N ; Pedrosa, Tatiana ; Fusco, Solange R G ; Rojo, Priscila T ; Pereira, Rosa M R ; Shinjo, Samuel K ; Andrade, Danieli C O ; Sampaio-Barros, Percival D ; Ribeiro, Carolina T ; Deveza, Giordano B H ; Martins, Victor A O ; Silva, Clovis A ; Lopes, Marta H ; Duarte, Alberto J S ; Antonangelo, Leila ; Sabino, Ester C ; Kallas, Esper G ; Pasoto, Sandra G ; Bonfa, Eloisa

Nature medicine, 2021-10, Vol.27 (10), p.1744-1751 [Periódico revisado por pares]

United States: Nature Publishing Group

Texto completo disponível

Citações Citado por

Enviar para

Título:
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
Autor: Medeiros-Ribeiro, Ana C ; Aikawa, Nadia E ; Saad, Carla G S ; Yuki, Emily F N ; Pedrosa, Tatiana ; Fusco, Solange R G ; Rojo, Priscila T ; Pereira, Rosa M R ; Shinjo, Samuel K ; Andrade, Danieli C O ; Sampaio-Barros, Percival D ; Ribeiro, Carolina T ; Deveza, Giordano B H ; Martins, Victor A O ; Silva, Clovis A ; Lopes, Marta H ; Duarte, Alberto J S ; Antonangelo, Leila ; Sabino, Ester C ; Kallas, Esper G ; Pasoto, Sandra G ; Bonfa, Eloisa
Assuntos: Adult ; Adults ; Adverse events ; Analysis ; Antibodies ; Antibodies, Neutralizing - biosynthesis ; Antibodies, Neutralizing - immunology ; Antibodies, Viral - biosynthesis ; Antibodies, Viral - immunology ; Autoimmune Diseases - complications ; Care and treatment ; COVID-19 - complications ; COVID-19 - prevention & control ; COVID-19 - virology ; COVID-19 vaccines ; COVID-19 Vaccines - adverse effects ; COVID-19 Vaccines - immunology ; Deactivation ; Diagnosis ; Female ; Human immunogenetics ; Humans ; Immunogenicity ; Immunoglobulin G ; Male ; Middle Aged ; Neutralization ; Neutralizing ; Rheumatic diseases ; Rheumatic Diseases - complications ; Safety ; Seroconversion ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Sex ; Vaccination ; Vaccines ; Viruses
É parte de: Nature medicine, 2021-10, Vol.27 (10), p.1744-1751
Descrição: CoronaVac, an inactivated SARS-CoV-2 vaccine, has been approved for emergency use in several countries. However, its immunogenicity in immunocompromised individuals has not been well established. We initiated a prospective phase 4 controlled trial (no. NCT04754698, CoronavRheum) in 910 adults with autoimmune rheumatic diseases (ARD) and 182 age- and sex-frequency-matched healthy adults (control group, CG), who received two doses of CoronaVac. The primary outcomes were reduction of ≥15% in both anti-SARS-CoV-2 IgG seroconversion (SC) and neutralizing antibody (NAb) positivity 6 weeks (day 69 (D69)) after the second dose in the ARD group compared with that in the CG. Secondary outcomes were IgG SC and NAb positivity at D28, IgG titers and neutralizing activity at D28 and D69 and vaccine safety. Prespecified endpoints were met, with lower anti-SARS-Cov-2 IgG SC (70.4 versus 95.5%, P < 0.001) and NAb positivity (56.3 versus 79.3%, P < 0.001) at D69 in the ARD group than in the CG. Moreover, IgG titers (12.1 versus 29.7, P < 0.001) and median neutralization activity (58.7 versus 64.5%, P = 0.013) were also lower at D69 in patients with ARD. At D28, patients with ARD presented with lower IgG frequency (18.7 versus 34.6%, P < 0.001) and NAb positivity (20.6 versus 36.3%, P < 0.001) than that of the CG. There were no moderate/severe adverse events. These data support the use of CoronaVac in patients with ARD, suggesting reduced but acceptable short-term immunogenicity. The trial is still ongoing to evaluate the long-term effectiveness/immunogenicity.
Editor: United States: Nature Publishing Group
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 10 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial

United States: Nature Publishing Group

Buscando em bases de dados remotas. Favor aguardar.